Showing 241-250 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Genetic Engineering to Improve Engraftment of Stem Cell-Derived Islets | Washington University | Jeffrey Millman | Cures | 01-February-2023 to 31-January-2026 | $450.000,00 |
| Pilot Brief Communal Coping Intervention for Adults with Type 1 Diabetes | Carnegie Mellon University | Vicki Helgeson | Improving Lives | 01-July-2023 to 30-April-2026 | $600.541,30 |
| Transdisciplinary Care for Young Adults with Type 1 Diabetes Transitioning to Adult Healthcare | Nemours Children's Clinic | Jessica Pierce | Improving Lives | 01-May-2023 to 30-April-2026 | $628.819,87 |
| Identifying the temporal functions of beta cell UPR in T1D | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Feyza Engin | Cures | 01-February-2023 to 31-January-2026 | $750.000,00 |
| The T1D Parent Check-In: A Preventative Intervention | Massachusetts General Hospital | Ellen O'Donnell | Improving Lives | 01-July-2023 to 30-June-2026 | $390.792,17 |
| Development of a Microfluidic Patch Pump for Next-Generation Wearable Artificial Pancreas Systems | University of California, Santa Barbara | Sumita Pennathur | Improving Lives | 01-May-2023 to 30-April-2026 | $1.065.254,36 |
| Type 1 Diabetes Consortium – Core and Prevention Workstream | Critical Path Institute (C-Path) | Sarah David | Cures | 01-July-2022 to 30-June-2025 | $800.270,00 |
| Towards FDA approval of Autonomous AI for diabetic retinopathy screening in youth | Johns Hopkins University | Risa Wolf | Improving Lives | 01-January-2023 to 31-December-2025 | $637.547,20 |
| Evaluating the Initial Efficacy, Acceptability, and Feasibility of BFST-DT, an Intervention for Improving Transition Readiness for Adolescents and Emerging Adults with Type 1 Diabetes | Ann & Robert H. Lurie Children’s Hospital of Chicago | Jaclyn Papadakis | Improving Lives | 01-May-2023 to 30-April-2027 | $396.471,68 |
| Addressing and mitigating sources of variability for the controlled and automated manufacturing of stem cell-derived beta (SC-beta) cells from pluripotent stem cells (PSCs) | Advanced Regenerative Manufacturing Institute (ARMI) | Thomas Bollenbach | Cures | 01-January-2023 to 31-December-2026 | $1.241.255,20 |